OP-2024

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameOP-2024
Drug Alias Nameanti-Parkinsonian therapy (Ohara Pharmaceutical)OP-2024
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOhara Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOhara Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A